www.innovotech.ca © innovotech, 2009 annual general meeting 20 april 2010 edmonton, alberta...
TRANSCRIPT
www.innovotech.ca © Innovotech, 2009
Annual General Meeting Annual General Meeting
20 April 201020 April 2010Edmonton, AlbertaEdmonton, Alberta
Innovotech Inc.Innovotech Inc.
www.innovotech.ca © Innovotech, 2009
A G E N D AA G E N D A WelcomeWelcome Formal Administrative BusinessFormal Administrative Business Adjournment of AGMAdjournment of AGM Business UpdateBusiness Update Q&AQ&A
Innovotech Inc.Innovotech Inc.
www.innovotech.ca © Innovotech, 2009
Formal Administrative BusinessFormal Administrative Business
Innovotech Inc.Innovotech Inc.
www.innovotech.ca © Innovotech, 2009
Election of Directors:Election of Directors: Dr Lorne BabiukDr Lorne Babiuk Mr Kerry Brown Mr Kerry Brown Mr Bruce D. Hirsche Q.C.Mr Bruce D. Hirsche Q.C. Dr Wolfgang H. MuhsDr Wolfgang H. Muhs Mr John PinsentMr John Pinsent Dr Gerard TertzakianDr Gerard Tertzakian Dr James TimourianDr James Timourian
Innovotech Inc.Innovotech Inc.
www.innovotech.ca © Innovotech, 2009
2009 – Moving to Market2009 – Moving to Market
Objectives & Performance in 2009Objectives & Performance in 2009
www.innovotech.ca © Innovotech, 2009
2009 Financial Results 2009 Financial Results
20092009 20082008
RevenueRevenue $1,453,924$1,453,924 $1,164,035$1,164,035
Gross MarginGross Margin $813,629$813,629 $695,409$695,409
Overhead CostsOverhead Costs $984,178$984,178 $909,588$909,588
R&D ExpendituresR&D Expenditures $809,326$809,326 $708,007$708,007
EBITEBIT ($1,136,783)($1,136,783) ($983,261)($983,261)
Accumulated DeficitAccumulated Deficit ($3,618,938)($3,618,938) ($2,491,735)($2,491,735)
Shares Outstanding Shares Outstanding (wa)(wa) 23,985,78423,985,784 21,907,35221,907,352
Cash Reserves (Dec 31)Cash Reserves (Dec 31) $1,375,559$1,375,559 $2,120,859$2,120,859
www.innovotech.ca © Innovotech, 2009
bioFILM PA - ObjectivesbioFILM PA - Objectives
bioFILM PA goals for 2009:bioFILM PA goals for 2009: RevenueRevenue Expand through commercial partnerExpand through commercial partner
Path:Path: Canada: Maintain current planCanada: Maintain current plan USA: “Research Use Only” through PartnerUSA: “Research Use Only” through Partner Convert to dry panelConvert to dry panel
www.innovotech.ca © Innovotech, 2009
bioFILM PA -Stakeholders bioFILM PA -Stakeholders
LaboratoryUser
DoctorsDecision-maker
Alberta HealthPayer
IOT
PatientsRecipient
www.innovotech.ca © Innovotech, 2009
bioFILM - Market potentialbioFILM - Market potential
Market - bioFILM PA:Market - bioFILM PA: CanadaCanada USUS WorldWorld Cystic FibrosisCystic Fibrosis $2.4M$2.4M $24M$24M $50M$50M Ventilator Associated PneumoniaVentilator Associated Pneumonia $35M$35M $70M$70M Other (burns, wounds)Other (burns, wounds) tbdtbd
Market – bioFILM SA:Market – bioFILM SA: CanadaCanada USUS WorldWorld CathetersCatheters DialysisDialysis Other (CF, VAP)Other (CF, VAP)
TotalTotal>$150M>$150M
www.innovotech.ca © Innovotech, 2009
bioFILM PA – 2010 ObjectivesbioFILM PA – 2010 Objectives
Revenue in CanadaRevenue in Canada Published paper Published paper Health economic evaluationHealth economic evaluation
Enter other marketsEnter other markets US through private diagnostic laboratoryUS through private diagnostic laboratory IsraelIsrael
SA developmentSA development Low cost and quick developmentLow cost and quick development Augments PA disease use (CF and VAP)Augments PA disease use (CF and VAP)
www.innovotech.ca © Innovotech, 2009
Agress – ObjectivesAgress – Objectives
Agress Agress goals for 2009:goals for 2009: Regulatory approval for pulsesRegulatory approval for pulses Commercial agreementCommercial agreement
Path:Path: Maintain current Co interestMaintain current Co interest Potential reg filing for Fire BlightPotential reg filing for Fire Blight Develop AUS R&DDevelop AUS R&D Launch in N America for pulses post-09Launch in N America for pulses post-09
www.innovotech.ca © Innovotech, 2009
Agress – PMRA (Canada) Agress – PMRA (Canada)
CurrentCurrent situation: situation: Innovotech denied waiver Innovotech denied waiver
claimsclaims Asked to re-submit with Asked to re-submit with
expedited review for expedited review for approved componentsapproved components
Fees partially refundedFees partially refunded 4 crops, 13 diseases, 1 use 4 crops, 13 diseases, 1 use
patternpattern
New submission:New submission: Determine EPA stanceDetermine EPA stance Use Syngenta regulatory Use Syngenta regulatory
teamteam Evaluate current consultantsEvaluate current consultants 8 crops, 25 diseases, 2 use 8 crops, 25 diseases, 2 use
patternspatterns
www.innovotech.ca © Innovotech, 2009
Agress – Syngenta partnershipAgress – Syngenta partnership
Agress to be used as “anti-bacterial” component of many Agress to be used as “anti-bacterial” component of many productsproducts
Syngenta press release on partnershipSyngenta press release on partnership Post-trade show orders of 1.5kg of AgressPost-trade show orders of 1.5kg of Agress Syngenta (US) interest in Pithium data in cornSyngenta (US) interest in Pithium data in corn
www.innovotech.ca © Innovotech, 2009
Agress – 2010 ObjectivesAgress – 2010 Objectives
Expand product claimsExpand product claims Crop, Disease and Use patternCrop, Disease and Use pattern Incorporate Syngenta trialsIncorporate Syngenta trials
Remove regulatory hurdlesRemove regulatory hurdles Meet with agenciesMeet with agencies Draw on external scientific expertiseDraw on external scientific expertise
Maintain flexibility with other companiesMaintain flexibility with other companies
www.innovotech.ca © Innovotech, 2009
Silver Periodate opportunitySilver Periodate opportunity
Unique propertiesUnique properties Patentable discoveryPatentable discovery Interest of medical device and agriculture companiesInterest of medical device and agriculture companies Assembly of internal teamAssembly of internal team
www.innovotech.ca © Innovotech, 2009
2010 – Objectives2010 – Objectives
Our goals for 2010:Our goals for 2010: bioFILM PA™bioFILM PA™
Agress Agress
R&DR&D
Contract ResearchContract Research
RevenueRevenue Enter US marketEnter US market Expand claimsExpand claims Remove regulatory hurdlesRemove regulatory hurdles Product candidate from Silver periodateProduct candidate from Silver periodate Develop bioFILM SADevelop bioFILM SA Photo-dynamic approval as sanitizerPhoto-dynamic approval as sanitizer Revenue growthRevenue growth
www.innovotech.ca © Innovotech, 2009
Contact InformationContact Information
Ken Boutilier, President Ken Boutilier, President Innovotech Inc.Innovotech [email protected] Ph: 780-448-0585 ext 221Ph: 780-448-0585 ext 221Fax: 780-424-0941Fax: 780-424-0941
www.innovotech.ca © Innovotech, 2009
2008 Summary - Agress™2008 Summary - Agress™
Seed Treatment, Pulse cropsNorth America$3-5M
Seed Treatment, All cropsNorth America$120M
Seed & FoliarAll crops
World$20B+
Factors: Treatment is based on disease pressure Crop guarantees by sellers increases treatments A suitable antibacterial is lacking Formulations are as important as “actives” Agress will be in a combination with other agents